NGENLA is a brand name for a long-acting injectable medication primarily used in the treatment of growth hormone deficiency in both children and adults. It contains somapacitan as its active ingredient, which is a growth hormone analog designed to stimulate growth and cell reproduction. NGENLA works by mimicking the action of natural growth hormone in the body, thereby promoting bone and muscle growth, as well as affecting fat distribution and metabolism. It is administered through subcutaneous injection, and its long-acting formulation allows for less frequent dosing compared to traditional growth hormone therapies, potentially improving adherence and convenience for patients. As with any medication, the use of NGENLA should be under the guidance of a healthcare professional, and it is important for patients to be monitored for any side effects or adverse reactions.